Mediplantex profit surges 12% in Q3 despite revenue drop

Mediplantex National Pharmaceutical Joint Stock Company reported its Q3 2025 financial results, with profit after corporate income tax reaching VND 3,910,575,300, marking a 12% increase compared to Q3 2024. This growth occurred despite a 6% decrease in net revenue from sales and services, which totaled VND 87,136,699,490.

The company's gross profit from sales for the quarter was VND 17,849,240,948, a 16% decline from the previous year. However, strong financial management significantly reduced expenses. Selling expenses decreased by 38%, general and administrative expenses by 21%, and other expenses by 41%.

Operating profit for Q3 2025 rose by 12% to VND 5,039,143,038. The financial statements for the third quarter of 2025 were disclosed to the State Securities Commission and Hanoi Stock Exchange on October 17, 2025.